10694 studies found for:    NCI
Show Display Options
Rank Status Study
21 Recruiting Pomalidomide in Treating Younger Patients With Recurrent, Progressive or Refractory Central Nervous System Tumors
Conditions: Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Visual Pathway Glioma;   Refractory Central Nervous System Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Pomalidomide
22 Not yet recruiting Nivolumab and Ipilimumab in Treating Patients With Advanced HIV Associated Solid Tumors
Conditions: Adult Solid Neoplasm;   Anal Carcinoma;   HIV Infection;   Kaposi Sarcoma;   Lung Carcinoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
23 Not yet recruiting Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery
Conditions: Neurofibromatosis Type 1;   Plexiform Neurofibroma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Drug: Selumetinib
24 Not yet recruiting FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Stage IV Breast Cancer
Interventions: Procedure: Computed Tomography;   Radiation: F-18 16 Alpha-Fluoroestradiol;   Other: Laboratory Biomarker Analysis;   Procedure: Positron Emission Tomography
25 Not yet recruiting Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma
Conditions: Adult Brain Glioblastoma;   Recurrent Adult Brain Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Methoxyamine;   Drug: Temozolomide
26 Not yet recruiting FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia
Condition: Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Chemotherapy;   Procedure: Computed Tomography;   Drug: Cytarabine;   Other: Fluorothymidine F-18;   Other: Laboratory Biomarker Analysis;   Procedure: Positron Emission Tomography
27 Not yet recruiting Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
Conditions: Bile Duct Carcinoma;   Stage III Pancreatic Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Rectal Cancer;   Stage IIIA Small Intestinal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Rectal Cancer;   Stage IIIB Small Intestinal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Rectal Cancer;   Stage IV Gastric Cancer;   Stage IV Pancreatic Cancer;   Stage IV Small Intestinal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Ropidoxuridine
28 Not yet recruiting WEE1 Inhibitor MK-1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
Conditions: Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Belinostat;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: WEE1 Inhibitor MK-1775
29 Not yet recruiting Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin
Conditions: Human Papillomavirus Infection;   Stage IVA Hypopharyngeal Squamous Cell Carcinoma;   Stage IVA Laryngeal Squamous Cell Carcinoma;   Stage IVA Laryngeal Verrucous Carcinoma;   Stage IVA Oral Cavity Squamous Cell Carcinoma;   Stage IVA Oral Cavity Verrucous Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Hypopharyngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Verrucous Carcinoma;   Stage IVB Oral Cavity Squamous Cell Carcinoma;   Stage IVB Oral Cavity Verrucous Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma
Interventions: Drug: Cisplatin;   Drug: Hsp90 Inhibitor AT13387;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
30 Not yet recruiting Berberine Chloride in Treating Patients With Ulcerative Colitis in Remission
Condition: Ulcerative Colitis
Interventions: Drug: Berberine Chloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
31 Not yet recruiting Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
Conditions: Recurrent Uveal Melanoma;   Stage IV Uveal Melanoma
Interventions: Drug: Glembatumumab Vedotin;   Other: Laboratory Biomarker Analysis
32 Recruiting Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas or Diffuse Intrinsic Pontine Gliomas
Conditions: Diffuse Intrinsic Pontine Glioma;   Malignant Glioma;   Recurrent Childhood Brain Neoplasm
Interventions: Procedure: Diffusion Tensor Imaging;   Procedure: Diffusion Weighted Imaging;   Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging;   Procedure: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging;   Other: Laboratory Biomarker Analysis;   Procedure: Magnetic Resonance Spectroscopic Imaging;   Biological: Pembrolizumab;   Procedure: Perfusion Magnetic Resonance Imaging
33 Not yet recruiting Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers
Conditions: Lung Carcinoma;   Tobacco Use Disorder
Interventions: Drug: Aspirin;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Drug: Zileuton
34 Not yet recruiting Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
Conditions: Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Tumor;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Other: Pharmacological Study
35 Not yet recruiting Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma of the Skin;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Biological: Sargramostim
36 Not yet recruiting Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer
Conditions: Nasopharyngeal Nonkeratinizing Carcinoma;   Recurrent Nasopharyngeal Undifferentiated Carcinoma;   Stage III Nasopharyngeal Undifferentiated Carcinoma;   Stage IV Nasopharyngeal Undifferentiated Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
37 Not yet recruiting Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-versus-Host Disease
Condition: Progressive cGVHD
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Vismodegib
38 Recruiting Prostvac (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance
Conditions: Prostate Adenocarcinoma;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Other: Placebo;   Biological: Rilimogene-galvacirepvec
39 Not yet recruiting Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors
Condition: Malignant Digestive System Neoplasm
Interventions: Drug: Alisertib;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin
40 Not yet recruiting PARP Inhibitor BMN-673, Carboplatin, and Paclitaxel in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Condition: Adult Solid Neoplasm
Interventions: Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study;   Drug: Talazoparib

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years